)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
MAIA Biotechnology
MAIA Biotechnology (MAIA) investor relations material
MAIA Biotechnology Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary11 May, 2026
Executive summary
Clinical-stage biopharma focused on immunotherapies for cancer, with lead asset ateganosine (THIO) targeting NSCLC and other solid tumors.
Key milestones: $33M raised in March 2026 public offering, expansion of Phase 2/3 trials, and first U.S. clinical site activated for THIO-101.
Ongoing partnerships with Regeneron, BeOne, and Roche for clinical trials in multiple cancer indications.
Financial highlights
Cash increased to $34.4M as of March 31, 2026, from $8.7M at December 31, 2025, due to equity financing.
Net loss for Q1 2026 was $6.37M, up 41% year-over-year from $4.52M in Q1 2025.
Operating expenses rose 28% year-over-year, driven by higher R&D and G&A costs.
No revenue recognized; company remains pre-commercial.
Outlook and guidance
Net proceeds from March 2026 offering expected to fully fund ongoing pivotal Phase 3 trial for ateganosine in NSCLC.
Plans to initiate Phase 2 trials in HCC, CRC, and SCLC in 2026 and continue expansion into additional solid tumor indications.
Additional capital will be required for future operations and commercialization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MAIA Biotechnology
- Proxy statement amended to disclose equity compensation plan details and available shares.MAIA
Proxy filing27 Apr 2026 - Election of directors and auditor ratification headline the 2026 virtual annual meeting.MAIAProxy filing7 Apr 2026
- Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIAProxy filing7 Apr 2026
- Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIAQ4 202523 Mar 2026
- THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIABiotech Showcase 2025 Investor Conference10 Jan 2026
- Key votes include director elections, auditor ratification, and a major share authorization increase.MAIAProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor ratification, and doubling authorized shares.MAIAProxy Filing2 Dec 2025
- Shareholders to vote on director elections, auditor ratification, and doubling authorized common stock.MAIAProxy Filing2 Dec 2025
- Q3 2025 saw higher losses, key clinical progress, and a shift toward digital asset treasury.MAIAQ3 20257 Nov 2025
Next MAIA Biotechnology earnings date
AGM 202621 May, 2026
MAIA Biotechnology
Next MAIA Biotechnology earnings date
AGM 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage